News

We are advancing model informed drug development. In this video, Peter A Milligan describes our framework and some benefits of adopting these solutions across the project portfolio in terms of improved decision making, efficiency

We have been in the business for 8 years now. In this video Elodie Plan and Marie Sandström explain who we are and where we are heading.

We are happy to have Fanny onboard as a MIDD consultant. Her research experience includes PK/PD modeling and simulations of preclinical and clinical data in oncology. Fanny will first work from her

See the poster presentation of Population RTTE analysis of exacerbations in asthma patients by our MIDD Consultant Robin Svensson, presented at the American Conference on Pharmacometrics, November 2020

We are happy to have Andrea onboard as a MIDD consultant. Her research experience, from academia as well as pharmaceutical industry, includes PK/PD modeling and simulations in different therapeutic areas and concentration-QT analysis. Andrea will work from our Basel office in Switzerland. See her bio here

Pharmetheus will offer virtual professional pharmacometrics consulting sessions (~30 min), free of charge, between 5th and 20th of November in connection to the ACoP meeting.
Read more about the offer here.

Read more on the importance of collaboration for successful implementation Model Informed Drug Development. Richard Anziano, Chief Statistician and Peter A Milligan, CEO at Pharmetheus gives their perspective on this topic in the latest issue of Clinical Pharmacology & Therapeutics.Link to publication

Our Pharmetheus colleague Erik Sjögren is co-author to a new publication on physiologically based biopharmaceutics models. This workshop report summarizes the proceedings of Day 1 of a three-day workshop on “Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls”. Link to publication.